MediciNova (NASDAQ:MNOV – Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.0750 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.
MediciNova (NASDAQ:MNOV – Get Free Report) last released its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. MediciNova had a negative net margin of 1,962.98% and a negative return on equity of 27.28%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.19 million. On average, analysts expect MediciNova to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
MediciNova Price Performance
Shares of MediciNova stock opened at $1.32 on Wednesday. MediciNova has a 52-week low of $1.17 and a 52-week high of $1.96. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.42. The company has a market capitalization of $64.97 million, a P/E ratio of -5.74 and a beta of 0.63.
Analyst Ratings Changes
View Our Latest Stock Report on MediciNova
Hedge Funds Weigh In On MediciNova
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNOV. StoneX Group Inc. purchased a new position in MediciNova in the fourth quarter valued at approximately $25,000. Goldman Sachs Group Inc. purchased a new stake in shares of MediciNova during the 4th quarter worth approximately $35,000. Citadel Advisors LLC purchased a new stake in shares of MediciNova during the 3rd quarter worth approximately $92,000. Jane Street Group LLC acquired a new position in shares of MediciNova in the 4th quarter valued at $214,000. Finally, State Street Corp boosted its holdings in shares of MediciNova by 10.9% in the 4th quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 19,100 shares in the last quarter. 9.90% of the stock is owned by institutional investors and hedge funds.
MediciNova Company Profile
MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.
The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.
Read More
- Five stocks we like better than MediciNova
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
